A Phase II Randomized, Multicenter Study of Treatment-free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients Who Achieve and Sustain MR4.5 After Switching to Nilotinib
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2019
Price : $35 *
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms ENESTgoal
- Sponsors Novartis; Novartis Pharmaceuticals
- 05 Aug 2019 Status changed from active, no longer recruiting to completed.
- 25 Oct 2018 Planned End Date changed from 31 Jan 2021 to 1 Feb 2021.
- 25 Oct 2018 Planned primary completion date changed from 31 Jan 2021 to 1 Feb 2021.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History